

То:	Trust Board		Trust Board Paper X1				
From:	Andrew Seddon – Finance and Business	Director of Services					
Date:	25 April 2013						
CQC regulation:	All applicable						
Title:	2012/13 Year End Financial Position						
Author/Responsible Director: Andrew Seddon - Director of Finance and Business Services							
Purpose of th	e report: Trust Board on the year e	nd financial no	sition and cash halance				
	provided to the Trust Bo		Sition and cash balance				
Decis	sion	Discussion					
Assu	rance X	Endorsemer	nt				
Ourse and Ware Dainetes							
Summary/Key Points: The Trust has delivered a £90k surplus which is £44k favourable to the Plan of £46k surplus.							
The year end cash balance was £19.9m in excess of the £18m target.							
Recommendations: The Trust Board is asked to note the delivery of the key financial targets							
Strategic Risk Register: N/A Performance KPIs year to date: N/A							
Resource implications (e.g. Financial, HR): N/A							
Assurance implications:			N/A				
Patient and Public Involvement (PPI) implications:			Not at this stage				
Equality Impact:			Low				
Information exempt from disclosure:			N/A				
Requirement for further review:			No				

Andrew Seddon Director of Finance and Business Services

16 April 2013

UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST

REPORT TO: TRUST BOARD

DATE: 25 APRIL 2013

REPORT FROM: ANDREW SEDDON - DIRECTOR OF FINANCE & BUSINESS

SERVICES

SUBJECT: FINANCIAL PERFORMANCE IN 2012/13

1. Introduction

1.1 This paper summarises the year end financial position.

2. Financial position as at end of March 2013

- 2.1 The Trust is reporting a year end surplus of £90k, £44k favourable to Plan. Income is £35.8m (5%) over Plan, which is stated net of a £5.1m marginal rate deduction for emergency inpatient income over the 2008/09 baseline. Operating costs cumulatively are £36.1m over Plan, with premium cost staff largely being used to deliver the additional activity.
- 2.2 Table 1 outlines the current position and Table 2 outlines the Financial Risk Rating:

Table 1 – I&E Summary

		March 2013	3	April - March 2013				
	Plan	Actual	Var	Plan	Actual	Var		
	Piali	Actual		Fiaii	Actual			
	£m	£m	£m	£m	£m	£m		
Income								
Patient income	51.6	56.7	5.2	617.9	648.0	30.1		
Teaching, R&D	6.3	9.0	2.8	75.2	77.3	2.1		
Other operating Income	2.5	3.8	1.2	28.1	31.8	3.6		
Total Income	60.4	69.5	9.2	721.2	757.0	35.8		
Operating expenditure								
Pay	36.2	39.5	(3.3)	439.7	455.2	(15.5)		
Non-pay	20.5	24.8	(4.3)	237.9	258.5	(20.6)		
Total Operating Expenditure	56.7	64.3	(7.6)	677.6	713.7	(36.1)		
EBITDA	3.6	5.3	1.6	43.6	43.3	(0.3)		
Net interest	-	0.0	0.0	0.0		0.0		
Depreciation	(2.7)	(2.7)	0.0	(32.5)	(31.6)	0.9		
Loss on Fixed Asset Disposal	. '	(0.4)	(0.4)	` ,	(0.4)	(0.4)		
PDC dividend payable	(0.9)	(1.1)	(0.2)	(11.1)	` ,	(0.2)		
Net deficit	0.0	1.1	1.1	0.0		0.1		
EBITDA %		7.6%			5.7%			

The patient income line includes both NHS and non-NHS patient care income

Table 2 – Financial Risk Ratings

			Risk Ratings					
Criteria	Indicator	Weight	5	4	3	2	1	Forecast Outturn
Underlying performance	EBITDA margin %	25%	11	9	5	1	<1	3
Achievement of plan	EBITDA achieved %	10%	100	85	70	50	<50	4
Financial efficiency	Net return after financing %	20%	>3	2	-0.5	-5	<-5	5
Financial efficiency	I&E surplus margin %	20%	3	2	1	-2	<-2	2
Liquidity	Liquid ratio days	25%	60	25	15	10	<10	3
Overall rating								3

2.3 The **year end position** may be analysed as follows.

3. Income

- 3.1 NHS patient care income is £28.3m (4.6%) favourable to Plan. However, the £28.3m over performance includes £21m in relation to the UHL/CCG year end agreement. The £21m can be broken down into the following 3 sections:
 - £7.5m from the Local Area Team
 - £7.0m from the CCG
 - £6.5m from the CCG to reflect the re-investment of the penalties around ED performance and the 62 day Cancer Target
- 3.2 The first 2 funding sources predominately secure re-imbursement for the MRET reduction (£5m) and performance penalties (£8m) and a contribution to the marginal costs of the extra capacity required.

4. Expenditure

- 4.1 **Operating expenditure** for the year is £36.1 (5.3%) adverse to Plan, comprising of pay at £15.5m (3.5%) adverse and non-pay £20.6m (8.7%) adverse.
- 4.2 **CIP performance** was £26.8m savings delivered, £5.2m adverse to the Plan of £32m.
- 4.3 **The pay position**, the year end position of £15.5m adverse to Plan is as a result of a number of key factors:
 - The use of extra capacity wards (Fielding Johnson, Ward 1 LRI; Ward 2 LGH; Ward 19 LRI and Odames LRI total of 84 beds) to meet the emergency activity levels. Pay spend on these 3 wards is in excess of £5m.
 - The Acute Care Division is also rostering more doctors and nurses in Medicine and ED to ensure the flow of patients from ED to support the 4 hour target. £2.7m (17%) increase in ED pay costs in 2012/13 compared to 2011/12 (activity increase of 3.8%).
 - An increased reliance on premium payments.

- 4.4 **Non-pay costs** operating non pay costs are reporting a year end adverse position against Plan of £20.6m.
- 4.5 The key areas are drugs, £3.7m adverse to Plan, and clinical supplies, £5.8m adverse, with variances in both categories driven in part by increased activity levels.

5. Cash

5.1 The Trust delivered the £19.9m cash balance at the end of the year against the £18m target.

6. Conclusion

6.1 The Trust Board is asked to **note** the delivery of the year end surplus and the year end cash target.

Andrew Seddon Director of Finance and Business Services

16 April 2013